A5067595603- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Radiation Therapy and Dosimetry
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Medical Imaging Techniques and Applications
- Advances in Oncology and Radiotherapy
- Intracranial Aneurysms: Treatment and Complications
- Ocular Oncology and Treatments
- Atomic and Subatomic Physics Research
- Gut microbiota and health
- Cellular transport and secretion
- Economic and Financial Impacts of Cancer
- COVID-19 and Mental Health
- Head and Neck Surgical Oncology
- Lysosomal Storage Disorders Research
- Boron Compounds in Chemistry
- Breast Cancer Treatment Studies
- Global Cancer Incidence and Screening
- Glycosylation and Glycoproteins Research
Rutgers, The State University of New Jersey
2022-2025
Rutgers Sexual and Reproductive Health and Rights
2025
Johnson University
2022-2024
Robert Wood Johnson University Hospital
2024
Mount Sinai Hospital
2024
Columbia University Irving Medical Center
2019-2024
Herbert Irving Comprehensive Cancer Center
2024
Waterbury Hospital
2021-2023
Emory University
2023
The Christie NHS Foundation Trust
2017-2023
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers the US and Europe. Thirty-one harbored t(11;14), 11 did not, one status was unknown. Patients received a venetoclax-containing regimen for at least 21- or 28-day cycle; median prior treatments three. The hematologic response rate all 68%; 63% achieved VGPR/CR....
No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess efficacy and safety bendamustine with dexamethasone (ben-dex) patients persistent or progressive AL amyloidosis after ≥ 1 prior therapy.The enrolled 31 who received on days 2 (100 mg/m2 intravenously) 40 mg weekly 28-day cycles until disease progression up 6 complete...
Abstract The gut microbiome influences immune and metabolic homeostasis. Our research using non-obese diabetic (NOD) mice revealed that early-life antibiotic exposure remodels the affecting metabolism accelerating type 1 diabetes (T1D) incidence, with cecal material transplant (CMT) mitigating damage. Now examining murine intestinal lipidomic profiles, we identified 747 compounds. Comparing profiles of contents conventional germ-free their diets, 87 microbially-produced lipids reduced by but...
Angiogenesis is critical for tumor growth and survival involves interactions between cancer endothelial cells. Prostate-specific membrane antigen (PSMA/FOLH1) expressed in the neovasculature of several types cancer. However, study neovascular PSMA expression has been impeded as human umbilical vein cell (HUVEC) cultures are PSMA-negative both xenografts patient-derived xenograft (PDX) models not known to express their vasculature. Therefore, was examined HUVECs, vitro vivo, we tested...
Esophageal squamous cell carcinoma (ESCC) is one of the most lethal cancers worldwide and evolves often to lung metastasis. P53 R175H (homologous Trp53 R172H in mice) a common hot spot mutation. How metastasis regulated by p53 ESCC remains be investigated. To investigate -mediated molecular mechanisms, we used carcinogen-induced approach R172H/− mice model ESCC. In primary tumor lines, depleted (shTrp53) observed marked reduction invasion vitro burden tail-vein injection comparing isogenic...
Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition standard anti-myeloma therapy unclear. This meta-analysis included 2340 MM (1982 with risk 358 high cytogenetics) 673 (513 160 assess which cytogenetic subgroups derived PFS Daratumumab. Studies were CASSIOPEIA, MAIA ALCYONE (for MM) CASTOR POLLUX trials MM). Daratumumab's led a clear (HR 0.43; 95% CI, 0.35-0.53; P < .05) both disease...
Silent brain infarcts are common in patients at increased risk of stroke and associated with a poor prognosis. In asymptomatic carotid stenosis, similar adverse associations were claimed, but the impact previous infarction or symptoms on beneficial effects endarterectomy is not clear. Our aim was to evaluate prior cerebral enrolled Asymptomatic Carotid Surgery Trial, large trial 10-year follow-up which participants whose stenosis had caused for least six months randomly allocated either...
Gigaxonin (also known as KLHL16) is an E3 ligase adaptor protein that promotes the ubiquitination and degradation of intermediate filament (IF) proteins. Mutations in human gigaxonin cause fatal neurodegenerative disease giant axonal neuropathy (GAN), which IF proteins accumulate aggregate axons throughout nervous system, impairing neuronal function viability. Despite this pathophysiological significance, upstream regulation downstream effects normal aberrant remain incompletely understood....
Men with high-risk localized prostate cancer exhibit high rates of post-surgical recurrence. In these patients, androgen deprivation therapy (ADT) is immunomodulatory, however increased infiltration regulatory T cells (Tregs) may limit the antitumor immune effects ADT. We designed a neoadjuvant clinical trial to test whether BMS-986218 - next-generation non-fucosylated anti-CTLA-4 antibody engineered for enhanced antibody-dependent cellular cytotoxicity or phagocytosis (ADCC/P) depletes...
Among racial subgroups, Black men have the highest prostate cancer-specific death rate, yet they also exhibit prolonged overall survival compared with White when treated standard therapies, including sipuleucel-T. Differential immune responses may play a role in these observations. We circulating markers from 54 (18 and 36 White) metastatic castrate-resistant cancer who received sipuleucel-T were enrolled on an monitoring registry. Markers included longitudinal serum cytokine concentrations,...
Abstract Background Immunosuppressive cytokines have the potential to promote prostate cancer progression. Assessing their longitudinal changes may implicate mechanisms of progression, treatment resistance, and suggest new therapeutic targets. Methods Thirty‐seven men with biochemically recurrent (BCR) who received 6 months androgen deprivation therapy (ADT) were monitored until time prostate‐specific antigen progression (TTPP) identified from a completed phase III trial (NCT00020085). Serum...
TPS4200 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease for which treatments result in limited benefit. Failure of immune checkpoint blockade attributed to multiple immunosuppressive pathways within the tumor microenvironment. The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C ligand 12 (CXCL12) axis results exclusion anti-tumor cells. Preclinical studies demonstrated that simultaneous CXCR4 inhibition (CXCR4i) and anti-programmed cell death 1...
5082 Background: Immunotherapy has limited efficacy in castration-resistant prostate cancer. Androgen deprivation therapy (ADT) significant immunomodulatory effects and initially induces a complex immune infiltrate before castration-resistance develops. However, ADT also recruits immunosuppressive myeloid cells to the tumor microenvironment by increasing interleukin-8 (IL-8). We conducted phase Ib/II clinical trial of immunotherapy plus men with recurrent castration-sensitive cancer (CSPC)....
8026 Background: Morbidity and mortality remain high in immunoglobulin light chain (AL) amyloidosis due to organ involvement despite hematologic remission. Few anti-amyloid fibril therapies for AL exist. We previously published the results of phase 1a/1b study CAEL-101 showing significant improvement response rates. 1 report long-term outcomes. Methods: Patients enrolled NCT02245867 with relapsed/refractory received 1a, a one-time dose-finding infusion 1b, 4 weekly infusions preplanned dose...
9592 Background: ICI responses in UM are rare (~5% with anti-CTLA4/PD1 monotherapy; 10-12% combination ICI). IMC is a bispecific agent composed of high affinity T cell receptor targeting the gp100 melanoma antigen fused to an anti-CD3 scFv that increases intratumoral CD8+ infiltration and PD1/PDL1 expression, may enhance response post-IMCgp100 ICI. Methods: We previously reported on 19 pts treated phase I dose escalation cohort (IMCgp100-102). performed retrospective analysis clinical...